-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Maintains Outperform on Merck & Co, Raises Price Target to $170

Benzinga·08/20/2026 17:17:32
Listen to the news
BMO Capital analyst Evan David Seigerman maintains Merck & Co (NYSE:MRK) with a Outperform and raises the price target from $142 to $170.